CD70 and clear cell renal carcinoma: Additionally, ALLO-316, an anti-CD70 CAR-T product, is being tested in the Phase 1 TRAVERSE study for patients with advanced or metastatic clear cell renal cell carcinoma (CcRCC) (90).